Media
Corgentech Will Present at the UBS Warburg Global Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2003 -- Corgentech Inc., a privately held biotechnology company, today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the upcoming UBS Warburg Global Life Sciences Conference. His presentation will be held on Tuesday, September 23 at 2:00 p.m. ET in the Versailles B Room at The Plaza Hotel in New York City.
McLaughlin will provide an update on the company's progress with its lead product, CGT003, an E2F Decoy, which is being evaluated in two Phase III clinical trials for prevention of graft failure following coronary and peripheral bypass surgery. He also will discuss other projects in the company's expanding pipeline based on its novel and versatile research platform, including the company's second product, CGT021, which will enter a Phase I/II clinical trial for the prevention of arterio-venous (AV) graft failure in End-Stage Renal Disease patients requiring hemodialysis next year.
The presentation and audio webcast will be available online live at 2:00 p.m. ET and by replay for 30 days. To listen to the webcast and view the slides, please visit our website at www.ibb.ubs.com at least fifteen minutes prior to the beginning of the scheduled presentation to register, download and install any necessary multimedia streaming software. Real Player or Windows Media Player are the required software plug-ins.
About Corgentech Inc.
Corgentech Inc. is a privately held biotechnology company that is the leader in the discovery, development and commercialization of an exciting and powerful new class of therapeutics called transcription factor decoys or TF Decoys. The company's proprietary technology platform is capable of delivering multiple new product candidates to treat diseases that affect large patient populations in a relatively short period of time. Currently, the company is focused in three therapeutic areas: cardiovascular disease, inflammatory disease and cancer. Corgentech is based in South San Francisco, Calif. For more information on the company and its technology, visit www.corgentech.com.
| Contacts: | |
| Richard Powers Corgentech |
Kristin Nash WeissCom Partners |
| 650-624-9600 [email protected] |
415-302-7951 [email protected] |
